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ARTICLE OPEN
Variable outcomes of human heart attack recapitulated in
genetically diverse mice
Ekaterina Salimova 1,2, Kristen J. Nowak3,4,5, Ana C. Estrada 6, Milena B. Furtado1,7, Elyshia McNamara3,4, Quang Nguyen4, Lois
Balmer4,8, Christoph Preuss9, Jeffrey W. Holmes6, Mirana Ramialison1, Grant Morahan3,4 and Nadia A. Rosenthal1,7,9
Clinical variation in patient responses to myocardial infarction (MI) has been difficult to model in laboratory animals. To assess the
genetic basis of variation in outcomes after heart attack, we characterized responses to acute MI in the Collaborative Cross (CC), a
multi-parental panel of genetically diverse mouse strains. Striking differences in post-MI functional, morphological, and myocardial
scar features were detected across 32 CC founder and recombinant inbred strains. Transcriptomic analyses revealed a plausible link
between increased intrinsic cardiac oxidative phosphorylation levels and MI-induced heart failure. The emergence of significant
quantitative trait loci for several post-MI traits indicates that utilizing CC strains is a valid approach for gene network discovery in
cardiovascular disease, enabling more accurate clinical risk assessment and prediction.
npj Regenerative Medicine             (2019) 4:5 ; https://doi.org/10.1038/s41536-019-0067-6
INTRODUCTION
The mortality rate among patients having heart failure (HF) with
reduced ejection fraction (EF) following a heart attack has
gradually been reduced through the cumulative benefit of
medications such as angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, β-blockers, and mineralocorticoid-
receptor antagonists.1,2 However, surviving patients with ischemic
cardiomyopathy and HF face a broad spectrum of symptoms,
emphasizing the need for new prognostic models to stratify
patient subgroups and to develop new therapies. Predominant
risk predictors include genetic factors, which have a profound
influence on incidence and outcome of cardiovascular disease.3–5
Mice have provided an effective experimental system to study
the general pathophysiology of heart disease, to identify
molecular markers and to assess therapeutic options. Inbred
mouse models comprise useful experimental systems for func-
tional analysis of genetic variants in the context of disease
phenotyping, with validation in controlled conditions, high
reproducibility, and unlimited access to tissues for the identifica-
tion of genes contributing to simple Mendelian traits. Even so,
experimental strategies for complex trait analyses in the mouse
have not kept pace with rapid developments in human genetic
studies, and thus new strategies for using model organisms are
needed. A major drawback of mouse models has been the limited
genetic diversity in inbred laboratory mouse strains, which do not
accurately capture the complex genetics of the human population.
With over 20,000 interacting mammalian genes, each with
multiple variants, genetically diverse experimental mouse systems
have proven a more powerful tool to dissect cardiovascular
features.6 Such systems are essential for building predictive
models of predisposing traits for outcomes with such a complex
etiology as cardiovascular disease and for making precision
medicine a reality.
The Collaborative Cross (CC) multi-parental recombinant inbred
(RI) panel was specifically designed for performing gene associa-
tion studies of complex human disease, with increased requisite
statistical power and resolution for mapping complex traits that
better reflects clinical genetic variation.7,8 The CC panel encom-
passes multiple RI mouse strains derived from eight founder
inbred mouse lines (A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/
H1LtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ), in which all strains inherit
different founder genome components through randomization.
The CC panel offers a tractable experimental system designed for
the correlation of phenotypes with underlying biomolecular,
physiological, and morphological characteristics. The CC harnesses
over 90% of common genetic variation of the mouse species. In
addition, genetic variation in CC RI strains is uniformly distributed,
with multiple allelic variants in the coding or regulatory regions of
essentially all known genes, in contrast to classical inbred strains
of mice, which have limited genetic diversity.9 The genetic
architecture of the CC population has been derived from complete
genome sequencing of 8 CC founder and 69 RI strains, revealing
high allelic diversity and affording precision mapping of
phenotypic quantitative trait loci (QTL).10 The CC panel serves as
a resource of stable genotypes for mechanistic analysis: each CC
inbred strain represents a fixed and reproducible genotype,
providing retrievable, genome-matched mice for experimental
replication, trait correlation, and mapping by association analysis,
affording resolution at least an order of magnitude better than
that achieved by traditional linkage methods. The CC also
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provides models of diseases not previously available in the mouse,
e.g., diabetic retinopathy.11
Reasoning that the CC panel could provide valuable insight into
the genetic complexity of cardiovascular disease, we carry out a
cardiac susceptibility pilot screen by subjecting cohorts of CC
strains to experimental myocardial infarction (MI)12 and evaluating
multiple parameters of injury response. Dramatic variation in MI
survival, cardiac dilation and scar size is scored in 32 CC founder
and RI lines. Cardiac gene expression profiling reveals enrichment
in metabolic features for specific traits, whilst genetic analysis
demonstrates distinct loci for parameters such as cardiac rupture
and HF (left ventricular dilation). Collectively, these results
highlight the variation in genetic factors influencing both acute
and chronic presentations of heart disease, and provide new,
genetically tractable models for dissecting the diversity of human
cardiomyopathies.
RESULTS
Variation in heart morphology and function across CC mouse
strains
A preliminary survey of CC founder and RI strains revealed marked
differences in various morphological parameters, e.g., coat color
and quality, body weight (BWt), behavior, neurological activity,
and bleeding (unpublished results), in accordance with previous
reports on variation in aspects such as motor performance,13
hematological parameters,14 susceptibility to infections,15–17
immunological conditions,18,19 reproduction,20 toxicokinetics,21
glycome repertoire,22 and traits associated with skin cancer.23
To assess parameters of cardiac morphology and function,
echocardiographic analysis was performed on 12-week-old male
mice from various CC RI strains, with particular focus on LV
function. We documented significant variation in LV morphology
(Fig. 1a) as well as other parameters, exemplified by LV wall
thickness, EF, and stroke volume (SV) (Fig. 1b–d). It was notable
that in certain CC RI strains LV mass did not show direct
correlation with BWt (Fig. 1e, f), as exemplified by the DAVIS_BA,
DONNELL_HA, FEW_FD, and POH_DC strains (colored arrows).
Although most strains had steady heart rates of 400–450 bpm
during ultrasound imaging under standard conditions (1.5% v/v
isoflurane anesthesia and a body temperature of 37 °C), some
strains revealed a tendency to maintain a stably higher
(>500 bpm, e.g., BEM_AG, DONNELL_HA, FEW_FD, POH_DC) or a
stably lower (<400 bpm, e.g., 129 × 1, NOD/ShiLtJ, PEF_EC) heart
rate (data not shown). These findings underscore the reproducible
variability among CC RI strains in virtually every parameter
measured. A complete summary of measurements and calcula-
tions is outlined in Table S1 (Supplementary Material).
Strain variation in perioperative survival after MI
After baseline ultrasound examination, mice were subjected to left
coronary artery (LCA) ligation surgery to model MI. Although all
assessed strains recovered normally immediately after surgery,
there was a significant difference in survival 3–5 days post MI
(Fig. 2). This survival drop-off prominent in some strains was due
to death by myocardial rupture, a typical feature of the mouse MI
model. Notably, the C57BL/6J (B6) parental strain (most widely
used in cardiovascular research) displayed one of the highest
mortality rates. Two CC RI strains (CIS_AD and MERCURI_HF) had
100% penetrance for this trait.
During surgical procedures, there were distinct morphological
differences among CC RI strains in trachea diameter and/or LCA
position and branching. Narrow/fragile trachea impeded success-
ful intubation, whereas early LCA branching and/or atypical
position was a major hindrance for obtaining a reproducible
infarct size. Thereafter, strains exhibiting such phenotypes were
excluded from further analysis (e.g., PUB_CD, TAS_FE, and
YOX_DE). For other strains, only those with a comparably large
MI size (~40% of LV) were included for further study; as from
previous studies24 and our observations, an MI size of <30% does
not result in significant reduction of EF and LV remodeling.
Post-MI diversity in heart function and morphology
Heart function of the surviving mice was assessed by echocardio-
graphy 1 month after MI surgery, at which point hearts were
collected and whole-mount images obtained (Fig. 3a). As with
baseline measurements, there was dramatic variation in the
outcome of MI between strains. Considering that reduced EF (ΔEF)
and LV dilation (LVD) are the key hallmarks of MI-induced LV
systolic dysfunction (LVSD) and subsequent HF,1,25,26 these two
parameters were assessed for each strain before and after MI.
Significant variation was detected between the strains, with B6
being one of the worst performing strains (Fig. 3b, c).
Strains displaying severe and minimal LVSD based on the
combination of ΔEF and LVD traits are highlighted on Fig. 3a in
red and green, respectively. Notably, some strains (e.g., GIT_GC,
GALASUPREME_CE, JUNIOR_GB, DOD_AH, HAZ_EF) did not show
evidence of a direct correlation between ΔEF and LVD traits. For
the consistency of the study, these were excluded from LVSD/HF-
related analysis. A complete summary of post-MI measurements
and calculations is presented in Table S2 (Supplementary
Material).
Of all the strains assessed, TOFU_FB exemplified an excellent
model of MI-induced dilated cardiomyopathy with 100% survival,
high phenotypic penetrance, and reproducibility of post-MI
response. Multiple animals of the NUK_AC strain manifested
various cardiac abnormalities in homeostatic condition, including
heart and right ventricular hypertrophy. These individual animals
were not included in this study (Fig. 3d).
Reasoning that scar quality and composition might correlate
with LVD, scar analysis was performed on eight selected CC RI
strains, with differentially pronounced LVSD/HF phenotype.
Significant differences in apparent wall thickness in the embedded
scar samples ranged from an average of 100 µm for the BOON_HF
strain to over 250 µm for the BOM_GB strain (Fig. 4a). The collagen
area fraction (AF) was high in most strains, with substantial inter-
sample variability (Fig. 4b). Two of the CC RI strains (FEW_FD and
NUK_AC) showed significant collagen fiber alignment (Fig. 4c, d)
and in both cases the average orientation of the collagen fibers
was close to the circumferential direction. Most other strains
showed collagen alignment patterns more similar to that reported
following coronary artery ligation in rats.27 Individual scars often
displayed substantial alignment as indicated by a mean vector
length (MVL) of 0.4 or higher, but the group did not display
significant alignment on average, because the mean orientation
varied between samples. In summary, whereas collagen content
was similar across strains, strength of collagen alignment varied
widely.
Distinct genetics of heart repair vs ear hole punch healing
To compare the efficiency of heart repair with a recognized model
of tissue regeneration established with the Murphy Roths Large
(MRL/MpJ) mouse strain,28 ear punch closure analysis was
performed on selected CC RI strains. Surprisingly, no direct
correlation between these two regenerative scenarios was seen
(Fig. 5). Specifically, the BEM_AG and PEF_EC strains recovered
relatively well from MI response, yet were not as efficient in ear
punch hole healing. By contrast, the BOON_HF and FEW_FD
strains responded poorly to the MI challenge, yet healed ear
punch holes effectively. These results support the presence of
distinct genetic programs underlying cardiac vs. ear wound repair.
E. Salimova et al.
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Fig. 1 Comparative morphological and functional analysis of selected CC RI strains (12-week-old male mice). a Representative echographic
images of the left ventricles in longitudinal axis. b–f Plots showing distribution of individual values among RI strains for b LV wall thickness in
diastole, c ejection fraction, d LV stroke volume, e body weight (BWt), and f LV mass (calculations based on echographic measurements).
Colored arrows point at the strains with most prominent differences between BWt and LV weight. Scale bar, 5 mm a
E. Salimova et al.
3
Published in partnership with the Australian Regenerative Medicine Institute npj Regenerative Medicine (2019)     5 
Cardiac gene expression profiling and functional annotation
To highlight the molecular differences among CC hearts that
might predict functional variation in in cardiac injury response, we
performed systematic gene expression profiling on the uninjured
hearts of selected CC RI strains. Principal component analysis
(PCA) on whole-transcriptome profiles of 27 strains employed in
this study did not detect any clustering across strains on the
transcriptome-wide level that would correlate with the observed
cardiac injury response (Supplementary Fig. S1). Strains with
higher resilience in response to LVSD/HF did not cluster separately
from more susceptible strains.
To detect meaningful variations in gene expression that could
be indicative of predisposition to or protection from MI-induced
LVSD/HF, hierarchical clustering on genes was performed in the
12 strains with most pronounced dissimilarities in the LVSD/HF
phenotype (see Fig. 3a). No apparent clusters correlating with the
phenotype could be identified, in agreement with the PCA results.
However, when clustering was repeated on six strains from the
extremities of the LVSD/HD spectrum (FIM_DF, POH_DC, PEF_EC,
BOON_HF, DAVIS_BA, and B6; see Fig. 3a), five prominent clusters
of gene expression profiles displayed correlation with LVSD/HF.
Enrichment analysis using PANTHER29 and DAVID30 revealed one
cluster (Fig. 6a) enriched in genes involved in oxidative
phosphorylation (GO-Slim Biological Process GO:0006119, cor-
rected p-value= 2.02E− 04 and KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway mmu00190, corrected p-value=
2.33E− 05). A heatmap of the genes from PANTHER and DAVID
enrichment lists (Atp5a1, Ndufa5, Ndufa6, Ndufb5, Ndufb9,
Ndufa13, Ndufc1, Cox8b, Cox7b, Cyp4a31, Uqcrb (Fig. 6b))
evidenced reduced gene expression across the strains with
minimal LV remodeling and elevated gene expression in the
strains with distinct LVSD.
To validate this finding and to explore the connections between
individual gene expression levels and predicted LVSD/HF pheno-
types, GeneNetwork/WebQTL correlation analysis was performed
between the cardiac expression dataset and the LVD and ΔEF
traits using 12 strains most susceptible (B6, DAVIS_BA, BOON_HF,
TOFU_FB, 129 × 1, FEW_FD) and resilient (FIM_DF, POH_DC,
PEF_EC, BOM_GB, NUK_AC, SAT_GA) to LVSD/HF (see Fig. 3a). Of
the 500 top candidate genes with a correlation coefficient above
± 0.60, 343 were common for both traits. Enrichment tests on
these 343 correlates revealed the “generation of precursor
metabolites and energy” (GO:0006091) and “oxidative phosphor-
ylation” (mmu00190) terms being overrepresented (corrected
p-values= 4.35E− 02 and 1.49E− 03, respectively) comprising
Atp5a1, Atp5e, Atp5k, Cox7b, Ndufb4, Ndufb5, Ndufb9, Sdhd, and
Uqcrb. All these genes displayed positive correlations between
messenger RNA expression and adverse MI outcome. Usmg5 (also
known as Atp5md; ATP synthase membrane subunit DAPIT) was
one of the top scoring correlates on the list (Fig. 6c) and had
expression also positively correlating with the LVSD/HF pheno-
type. Usmg5 co-purifies with mitochondrial ATP synthase31 and is
critical for maintaining its function.32 Collectively, these data
support a plausible connection between elevated intrinsic levels
of oxidative phosphorylation and predisposition to LVSD/HF.
Notably, the top negative correlate Nab1 (Ngfi-A-binding protein
1; Fig. 6d) is a transcriptional repressor described as a negative
regulator of pathological cardiac hypertrophy.33
A summary of the 50 top correlates common for LVD and Δ%EF
traits is presented in Table S3 (Supplementary Material). In addition,
two other genes with expression positively correlating with the
LVSD/HF phenotype are worth noting: (1) Traf3 (tumor necrosis
factor receptor-associated factor 3), a major regulator of the innate
immune response with expression levels associated with neurolo-
gical and cardiovascular diseases;34 and (2) Cxcl9, a chemokine
associated with various pathological conditions including dilated
cardiomyopathy, HF, arrhythmias, and heart transplant rejection.35
Quantitative trait locus analysis
Quantitative trait locus (QTL) analysis of variation in MI response
revealed one significant QTL (P ≤ 0.05) on Chr 12 (logarithm of the
odds (LODs)= 10.3) for susceptibility to myocardial rupture
(survival) (Fig. 7a, b). This QTL spans the region
91.430–92.280 Mbp. At this region, the PWK/PhJ and CAST/EiJ
founder strains have predominant influences on the trait, with the
effects of the PWK strain being significant (P < 0.0001; indicated by
the red and green intervals in Fig. 7c, respectively; the founder
effects summary in Fig. 7d and the haplotype plots sorted by
phenotypic effect, Fig. 7e). The − 2 LOD drop region includes only
three protein coding genes: Nrxn3, Dio2, and Cep128. However, all
missense single nucleotide polymorphisms (SNPs) in this region
are contained within Cep128. This gene encodes a centriole
appendage protein negatively regulating ciliogenesis36 that has a
central role in pathogenesis of human congenital heart disease.37
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Fig. 2 Susceptibility of selected CC strains to myocardial rupture. Survival rate of mice 3–5 days after MI corresponding to mortality due to
myocardial rupture. Only animals with > 30% LV ischemia were included in the calculation. Initial number of animals per strain is indicated in
brackets next to the strain name (n)
E. Salimova et al.
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Fig. 3 Morphological and functional analysis of the hearts one month after MI. a Representative images of the hearts of selected CC RI strains
one month after MI, aligned from the most pronounced (top, in red) to the least pronounced (bottom, in green) LVSD/HF phenotype. b
Changes in EF for individual strains (green bars—before, red bars—1m after MI). Strains are aligned according to the degree of EF reduction
after MI (ΔEF—blue dots). c LV volume changes (green bars—before, red bars—1m after MI). Strains are aligned according to the degree of LV
dilation after MI (LVD—blue dots). Green and red arrows on X axis indicate the strains with correlating ΔEF and LVD values (LVSD/HF
phenotype). Error bars on the graphs denote standard deviation. Data are presented as mean value ± SD of minimum three biological
replicates. (Exact number biological replicates per strain is provided in Supplementary Tables S1 and S2.) d TOFU_FB strain as a potential
model of MI-induced dilated cardiomyopathy. Representative echographic images of the LV in longitudinal axis before (top) and after MI
(middle), whole-mount image of the same heart one month after MI (bottom). e NUK_AC strain as a potential model of spontaneous right
ventricular hypertrophy. Normal heart (left), heart with severe RV hypertrophy (right). Scale bars, 5 mm (a, d)
E. Salimova et al.
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Of the nine missense SNPs in Cep128, four were unique for the PWK
haplotype: rs261503899 (C > T), rs46662645 (A > T), rs262007891 (G
> C), and rs266165675 (C > T) (p-value 1.48e− 07); and four to both
the PWK and CAST haplotypes: rs252980304 (C > T), rs48026157
(A > C), rs51557552 (T > C), and rs46446778 (T > C) (P= 1.06e− 05).
This indicates that Cep128 is an excellent candidate for the causative
gene for cardiac rupture at this locus, with the abovementioned SNPs
mediating the myocardial rupture trait.
Fig. 4 Comparative morphological and qualitative analysis of the LV scars one month after MI. a Scar wall thickness. b Collagen area fraction. c
Analysis of collagen fiber alignment. The FEW_FD and NUK_AC strains show consistent alignment as determined by a one-sample t-test. d
Representative images of well-aligned (top) and poorly aligned (bottom) collagen fibers (polarized microscopy). Scale bar, 100 µm d
E. Salimova et al.
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Another QTL approaching significance (P ≤ 0.10) was associated
with the LVD trait (Fig. 8a, b). This QTL is located on Chr 5 (LOD=
9.1) and falls into the region 112,310–113,205 Mbp containing
multiple genes (Cryba4, Tpst2, Tfip1, Srrd, Gm6583, Hps4, Sez6l,
Asphd2, Gm6588, and Myo18b). Both the CAST/EiJ and C57BL/6J
parental strains displayed significant effects with this QTL
(Fig. 8c–e), suggesting that both strains harbor SNP(s) that
mediate predisposition to LVD (p-value 9.64e− 04). Although
the majority of significantly associated SNPs in the Chr 5 QTL
region were specific to the CAST haplotype, nine SNPs were
present both in CAST and B6, specifically rs33218387 (G > A),
rs253490750 (C > T), rs228327059 (C > T), rs32116976 (C > T),
rs32122208 (G > A), rs32118052 (G > C) and rs32118955 (C > T),
and rs47968507 (G > C) and rs46076017 (T > C). These SNPs would
be the best candidates to explain the QTL.
Remarkably, 24 of the missense SNPs significantly associated
with this QTL reside in Myo18b, with two of these (rs47968507
(G/C) and rs46076017 (T/C)) shared by both B6 and CAST. Myo18b
has been implicated in sarcomere assembly and maintenance of
myofibril structure38 as well as human skeletal and cardiomyo-
pathies when mutated.39,40 In addition, a polymorphism in Sez6l
has been associated with ischemic heart disease in humans41 and
five SNPs in Sez6l are significantly associated with the LVD trait.
A full list of SNPs associated with the two QTL, including their
precise genomic location and predicted effects on protein
function, is presented in Tables S4 and S5 (Supplementary
Fig. 5 Comparative analysis of heart vs. ear regeneration. a Representative images of selected CC strains one month after MI and ear punch. In
green, strains with minimal LV remodeling after MI, and in red, strains with adverse LV remodeling after MI. Note the poor correlation of the
degree of ear punch healing with the outcome of MI. Scale bars, 5 mm (heart images) and 1mm (ear punch images). b Quantification of the
ear punch hole area. Data are presented as mean value ± SD of minimum three biological replicates
E. Salimova et al.
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Fig. 6 Expression profiling and functional annotation clustering. a A heatmap of a selected gene expression cluster correlating with MI-
induced left ventricular systolic dysfunction (LVSD) and heart failure (HF) phenotype. The FIM, POH, and PEF strains displayed minimal LVSD,
whereas the B6, DAVIS, and BOON strains displayed severe LVSD after MI (see Fig. 3A). b Expression profile of genes involved in oxidative
phosphorylation overrepresented in cluster a (p-value > 2.00E− 04). c–e Representative correlation plots of top correlates of gene expression
vs. LVSD/HF-related traits (LVD and ΔEF). c Positive correlation of Usmg5 mRNA expression levels with the LVD phenotype (correlation
coefficient − 0.92, p-value= 1.88E− 06). d Negative correlation of Nab1 mRNA expression levels with the ΔEF phenotype (correlation
coefficient − 0.90, p-value= 9.50E− 06). e Positive correlation of Atp5k mRNA expression levels with the LVD phenotype (correlation
coefficient − 0.87, p-value= 7.91E− 05)
E. Salimova et al.
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Material). All other traits analyzed (e.g., BWt, LV mass, heart rate,
EF, and EF change (%EF and Δ%EF), LV SV, LV wall thickness) did
not produce QTL with a P < 0.10, although some did have a
suggestive P < 0.63.
DISCUSSION
It is widely recognized that most common human pathologies
such as heart disease are genetically complex, requiring analysis of
Fig. 7 QTL mapping of the myocardial rupture trait. a A QTL map from a genome-wide scan comparing CC strains according to the
myocardial rupture trait value. Chromosomal positions are presented on the X axis, whereas the Y axis shows LOD scores. The three
significance threshold lines (from bottom to top) correspond to genome-wide permutation P-values < 0.63 (suggestive) < 0.10 (approaching
significance) and ≤ 0.05 (significant, in red). b A QTL map of chromosome 12 containing the locus with the greatest LOD score for this trait. c A
founder coefficient plot showing the contribution of the eight CC founder alleles at each position along chromosome 12. Note that the
chromosomal positions in parts B and C line up, allowing direct comparison. d At this QTL, the PWK founder strain has a significant effect on
the trait. e A haplotype figure showing the founder strain haplotype present in each CC strain at the peak QTL region. Note that three of the
five CC strains with the lowest values for this trait (at the top of the haplotype stack) have the PWK haplotype at this position, whereas two of
these five strains have the CAST haplotype. Genomic coordinates are relative to the NCBI37/mm9 mouse genome assembly
E. Salimova et al.
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many thousands of individuals to achieve adequate statistical
power for effective genetic dissection. Inbred mice are ideal model
organisms for systems genetic analysis, but have been only
modestly successful in mirroring human traits due to their limited
genetic diversity. Key limitations in complex genetic mapping
using inbred mice include low resolution of linkage approaches, a
high degree of false positive signals found in murine association
mapping (itself due to higher linkage disequilibrium among the
common laboratory strains),42,43 and the critical need for
permanent resources to apply systems-based approaches.
Fig. 8 QTL mapping of the left ventricular dilation (LVD) trait. a A QTL map from a genome-wide scan comparing CC strains according to the
LVD trait value. See Fig. 7 for other details. b A QTL map of chromosome 5 containing the peak locus that is above the line indicating LOD
scores approaching significance. c A founder coefficient plot for chromosome 5 showing the contribution of the eight CC founder alleles at
each position along the chromosome. At the peak QTL region, the B6 and CAST founder strains have the most effect on the trait (positive
contribution). d Founder effects for chromosome 5 at the position of the greatest LOD score, showing significant contributions by the CAST
and B6 founder strains. e A haplotype figure showing founder strain haplotype present in each CC strain at the peak QTL region on
chromosome 5. Note that three of the five CC strains with the greatest values for this trait (at the bottom of the haplotype stack) have the B6
haplotype at this position, whereas two of these five strains have the CAST haplotype. Genomic coordinates are relative to the NCBI37/mm9
mouse genome assembly
E. Salimova et al.
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The genetically diverse CC mouse panel deployed here
redresses these shortcomings and has already been successfully
exploited to map genetic modifiers of many traits, including
susceptibility to infection,15–17 drug toxicity,21,44 motor perfor-
mance,13 hematological parameters,14 immunological condi-
tions,18,19 reproduction,20 glycome repertoire,22 and traits
associated with skin cancer.23 By employing the gold standard
model of experimental MI to recapitulate the outcomes of human
heart attack, the current study provides important insights into
the genetic variation in cardiac function and disease. It discloses
distinct genetic programs underlying specific aspects of cardiac
response, underscores the diversity of regenerative strategies in
different tissue types, and reveals novel factors and candidate
genes that can now be experimentally validated.
Differential susceptibility of common laboratory mouse strains
to myocardial rupture has been previously described.45,46 How-
ever, these studies were performed with a very limited number of
strains and no molecular determinants were identified. Increased
susceptibility of the B6 and 129 strains to myocardial rupture was
noted, with 129 substrains being the most affected (notably
previous reports used 129s6 and 129sv45,46).
The mapping power of genetic studies in mice has been limited
by the lack of high throughput experimental challenges that
accurately recapitulate human MI. Nevertheless, two significant
QTL were detected here that warrant functional validation. SNPs in
the Cep128 gene corresponding to the rupture-associated QTL on
Chr 12 suggest a possible molecular determinant of myocardial
wall strength, as the role of cilia in heart development and
congenital heart disease is well established.37,47,48 Primary cilia
and ciliogenesis are also required for cell migration essential for
organogenesis and tissue repair.49,50 Destabilization of the actin
cytoskeleton has been recognized as a dominant inducer of
ciliogenesis51 and roles of cilia in mechanotransduction are
reviewed in ref. 52. These considerations strongly implicate cilia-
related signaling in maintenance of LV integrity during the
inflammatory phase following MI that involves active actin
undefined and cell migration. Although Cep128 was not detected
in the recessive forward genetic screen that implicated several
genes related to ciliogenesis and cilia-mediated signal transduc-
tion in pathogenesis of congenital heart disorders,37 it is never-
theless highly plausible that SNPs in Cep128 affect maintenance of
LV myocardium integrity and repair during the highly migratory
inflammation phase post MI.
Of the significant SNPs in the Chr 5 QTL region, missense
variants in Myo18b are the most likely candidates for predisposi-
tion to cardiac dilation, considering the widely acknowledged role
of Myo18b in myofibril assembly and myopathies.38–40,53 However,
none of these are unique to CAST and B6—the only two strains
displaying significant founder effects for the LVD trait (see Table
S5). Therefore, it could be possible that a non-missense variant
that is in common for CAST and B6 but not present in any other
founder strains is the influential SNP for this trait. Alternatively, the
same trait in CAST and B6 could be due to different SNPs in each
strain. Moreover, the presence of the same SNPs in strains other
than CAST and B6 (e.g., rs47968507 (G/C) and rs46076017 (T/C);
Table S4) may be negated by other genomic contributions.
Polymorphisms in Sez6l, another gene within the QTL on Chr 5,
could be also contributing to the trait. In humans, the SEZ6L
polymorphism rs663048 has been associated with ischemic heart
disease and arterial hypertension.41 This specific SNP is not
recapitulated in the CC mouse population; however, the region is
highly conserved, and several other SNPs may influence the LVD
phenotype (e.g., rs32116976, rs32122208, rs32118052, and
rs32118955) (see Table S4). Indeed, it is possible that the
concerted action of multiple SNPs may contribute to compro-
mised function or levels of Myo18b and/or Sez6l protein, resulting
in predisposition to HF.
Our analyses focussed on missense and splice variants within
the − 2 LOD drop for both QTL, as no relevant nonsense,
frameshift, or insertion/deletion variants were detected. However,
we cannot rule out potential contribution of synonymous and/or
non-coding SNPs. Differences in gene expression levels (more
likely to be influenced by non-coding genetic variants) and
transcript stability or translation efficiency due to synonymous
changes,54 rather than changes in amino acid sequence of the
resulting protein, could conceivably influence the phenotypes we
measured. Moreover, the length of a microsatellite within an
intron of Myo18b correlates with LVD (Supplementary Fig. S2), so
this too may exert an effect, as intronic microsatellite instability
had been previously associated with disease states (reviewed in
ref. 55). Although neither Cep128 nor Myo18b were represented on
the gene expression array employed in this study, the results of
quantitative PCR on complementary DNA from a selected set of
CC RI strains using specific TaqMan gene expression assays
revealed no correlation between the polymorphisms in these
genes and the mRNA expression levels (Supplementary Fig. S3).
This implies that the polymorphisms in these genes may result in a
compromised function of Myo18 and Cep128 proteins rather than
in alteration of mRNA expression and/or stability.
As HF is a disease of bioenergetic imbalance, it is interesting
that several components of the oxidative phosphorylation
machinery were upregulated in strains with adverse MI outcome.
The heart is the greatest oxygen-consuming organ in the body,
with no excess capacity for ATP production vs. utilization. Energy
supply in the form of ATP is mandatory to sustain cardiac
contractile and relaxation functions, and 90% of this requirement
is met by mitochondrial oxidative phosphorylation that is finely
adjusted to energy needs.56 Mitochondrial dysfunction has a key
role in progression to HF, as evidenced by decreased ATP
production consistently observed in various models of HF
(reviewed in refs. 56,57) Thus, hearts with a higher intrinsic
metabolic state and high energy consumption due to increased
components of oxidative phosphorylation machinery (e.g., mito-
chondrial ATP synthases and ubiquinone oxidoreductase subunits)
may be more promptly compromised after acute MI stress.
Surpassing cardiac compensatory capacity results in suppression
of ATP production and progression to HF. Intrinsic oxidative
phosphorylation status and mitochondrial metabolic state could
therefore serve as a biomarker for long term MI outcome
prognosis, and as such represents an important target for
therapeutic intervention to improve cardiac function.58
Other notable variables in transcript analysis of CC hearts
include the following: (a) Nab1, a zinc finger transcription factor
expressed in mouse cardiac myocytes, endothelial cells, and
fibroblasts.33 Nab1 is a negative regulator of pathological cardiac
hypertrophy, as Nab1-overexpressing mice are resistant to ɑ- and
β-adrenergic stimulation ventricular hypertrophy;33 (b) Traf3, a
member of the TRAF adaptor protein family and a major regulator
of the innate immune response, which has been identified as a
positive regulator of cardiac hypertrophy in response to high
pressure levels both in mouse and human hearts;34,59 and (c)
Cxcl9, a circulating chemokine ligand of the CXCR3 receptor and
T-cell chemoattractant, reported to be a valid biomarker for the
development of LV dysfunction and HF.35,60 Thus, in homeostatic
conditions, cardiac Nab1, Traf3, and Cxcl9 levels may be predictive
of adverse LV remodeling in response to MI.
Given the importance of infarct scar size and properties to LV
function,61 it is interesting that features of infarct scar structure
quantified in this study did not correlate with post-infarction
dilation or changes in function in the subset of animals where this
was assessed. Collagen AF was fairly similar across the strains
analyzed and scars with lower AF tended to be thicker, suggesting
the total amount of collagen produced in each strain was
remarkably similar. Although the alignment of the collagen fibers
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varied widely across the strains, there was no clear relationship
between collagen alignment and the development of failure.
Recently, a correlation was reported between mononuclear
cardiomyocyte frequency, CM proliferation, post-MI outcome, and
expression of Tnni3k across strains of the Hybrid Mouse Diversity
Panel.62 However, Tnni3k genetic ablation had no effect on cardiac
function or response to injury,62 and in the current study no
correlation was observed between MI-induced HF phenotype in
CC RI strains and Tnni3k locus polymorphisms or mRNA expression
levels (Supplementary Fig. S2). Therefore, it is likely to be that this
genetic locus operates in concert with other modifiers to influence
CM proliferation and predisposition to heart disease.
The results of this pilot study demonstrate the power of genetic
mapping in the identification of new modifiers in heart disease
and underscore the added value of establishing mouse models
that more accurately reflect the variation in human pathology.
Large-scale human genome sequencing has empowered gene
association studies and promises to catalyze a transformation of
medicine. Deeper knowledge of human sequence variation and
application of systems approaches has already begun to enrich
our understanding of the diversity in disease across the human
population.63 The pace of translating human genome research,
and functionalizing these correlations for the practice of
healthcare will now be heavily reliant on the use of appropriate
organismal models that accurately reflect the human condition,
such as the CC used here. From a clinical perspective, the
development of predictive biomarker panels common to mouse
and man would allow susceptibilities to be detected and heart
disease to be treated much earlier than is currently possible. Such
panels would provide a rapid screen for cardiovascular disease
susceptibility and early-onset pathology, and could improve
disease management by providing markers for risk, early
detection, prognosis, and therapeutic response that would be
immediately applicable to pharmacological screening.
MATERIALS AND METHODS
Animal handling
All mouse experiments were performed at Monash University and The
University of Western Australia and were approved by the Animal Ethics
Committees from the respective university. The CC mouse lines were bred
and supplied by Geniad Pty Ltd (Perth, WA, Australia)64 and housed at the
Animal Resources Centre (Perth, WA, Australia). At 4–5 weeks of age, mice
of backcross generation > 25 were shipped to Monash Animal Services
where they were housed in temperature-controlled facilities on a 12 h
light/dark cycle with chow and water supplied ad libitum. Experiments
were performed on 12-week-old male mice, unless stated differently.
The only four CC founder strains available within Australia (A/JArc,
C57BL/6JArc, NOD/ShiLtJArc, and 129 × 1/SvJArc) were sourced from the
Animal Resources Centre (Perth, WA, Australia). The 129 × 1/SvJArc
substrain was used instead of 129S1/SvImJ, and therefore this strain was
excluded from the QTL analysis.
Selected RI strains in the CC panel have been maintained as
independent colonies for many generations in different international
locations and are therefore susceptible to genetic drift. The RI strains
analyzed in the current study were generated and maintained at the
Animal Resources Centre (ARC)/Geniad Pty Ltd (Western Australia), and
therefore the ARC/Geniad nomenclature has been retained to indicate
their specific origin. See Table S6 (Supplementary Material) for correspond-
ing nomenclature of the CC strains maintained at The Jackson Laboratory
and Table S7 (Supplementary Material) for abbreviations of the mouse
strains employed in this publication.
Ultrasound analysis
Cardiac morphological and functional parameters were assessed with a
Vevo2100 ultrasound imaging system (FUJIFILM/VisualSonics Inc., Canada)
with an ultra-high frequency linear array transducer (VisualSonics MS400,
18–38MHz). Mice were anesthetized with 4% isoflurane in oxygen and
placed in a supine position on a temperature-controlled imaging platform
under continuous supply of 1.5% isoflurane. Chest hair was removed using
a hair removal cream (Nair) and ultrasound transmission gel (Aquasonic,
Parker Laboratories, USA) was applied on the thorax. The heart rate was
continuously monitored and maintained at 400–450 bpm. Measurements
and calculations were performed using VevoLAB (v1.7) software package
(FUJIFILM/VisualSonics), presented in detail in Supplementary Material.
LVD parameter was calculated as % increase in LV volume after MI (LVD
= LV-volume;d-afterMI/LV-volume;d-beforeMI * 100− 100). ΔEF was calcu-
lated as % change in EF (ΔEF= (EF-beforeMI− EF-afterMI)/EF-afterMI *
100). Results are provided as a mean ± SD of the mean for 4–10 mice from
each CC strain. Data were analyzed using GraphPad Prism (v7) software
(IBM, Armonk, NY, USA).
Coronary artery ligation model of MI
The LCA was permanently ligated to model MI. Mice were anesthetized
with 4% v/v isoflurane, attached to an artificial respirator (SV of 200 µl at
120 strokes per min) via endotracheal cannulation and maintained under
2% v/v isoflurane anesthesia through the surgery. An incision was made
through the muscle between the fourth and fifth intercostal space to
access the heart. A 6mm tapered point needle with an 8-0 polyethylene
suture was passed through the myocardium underneath the LCA
approximately 1 mm below the tip of the left auricle. The ligature was
permanently tied around the LCA with three knots. The mouse thoracic
cavity was then closed and sutured. A 0.05 µg/g buprenorphine solution
was administered by subcutaneous injection twice daily for 3 consecutive
days post surgery. Mice were allowed to recover for 1 month and during
this time general condition and BWt were assessed at regular intervals.
Only mice with > 30% of LV ischemia were used for further analysis.
Specimen collection and histology
At experimental endpoint, mice were killed by CO2 asphyxiation and
perfused with phosphate buffered saline (PBS) to remove blood. Hearts
were excised, cleaned, fixed in 4% paraformaldehyde overnight and
washed in PBS. Imaging of whole-mount hearts was carried out using an
Olympus SZX16 stereo microscope equipped with an Olympus DP70
camera (Olympus, Japan) and running analySIS LS Starter v2.6 Software
(Olympus Soft Imaging Solutions, Germany). Samples were further
dehydrated and kept in 80% v/v ethanol at 4 °C for further experiments.
Scar morphology and quality analysis
Formalin-fixed hearts were divided into three transverse rings; the middle
ring, encompassing the region halfway between the base and the apex,
was used for histologic analysis. Scar samples extending from the anterior
RV insertion through a 90° arc toward the lateral well were cut from the
middle ring, dehydrated, transferred to paraffin, and embedded. Serial
sections of 7 µm thickness oriented parallel to the epicardial surface were
cut with a microtome (Leica) beginning at the epicardium and progressing
to the endocardium. The apparent wall thickness was calculated based on
the difference between the first and last sections that included tissue in
the center of the section. Sections representing the LV midwall (relative
depth between 40–60% of the total wall thickness) were stained with
picrosirius red for collagen and analyzed as described previously.27 An area
of approximately 1 mm2 (1.13 × 0.85mm) in the center of each midwall
section was imaged under circularly polarized light (collagen fibers appear
bright) and under brightfield illumination with a blue filter (collagen fibers
appear dark). These two images were subtracted to isolate the collagen
fibers, and the collagen AF and orientation were quantified by analyzing
the subtracted image with custom software (MatFiber, http://bme.virginia.
edu/holmes/downloads/index.html). Data were analyzed with circular
statistics, generating a mean vector for each sample, indicating the
average orientation (mean angle) and strength of alignment (MVL; 0 for
random and 1 for maximally aligned) of the collagen fibers. Collagen
alignment was considered statistically significant for a given strain if the
values MVLi * cos(2 * θi– 2*θm) were statistically different from 0 by a one-
sample t-test, where MVLi, θi are the length and orientation of the
individual sample vectors, and θm is the orientation of the group mean
vector.27
Cardiac gene expression analysis
Analysis of gene expression from the hearts of 55 CC strains was previously
described in ref. 65, with 27 of these strains being those analyzed in the
present study. Heart muscles were dissected immediately post-killing from
6-week-old, untreated CC male mice (n ≥ 3 per strain), snap frozen in liquid
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nitrogen, and stored at −80 °C until processing. An RNAeasy Fibrous Tissue
kit (Qiagen) was used to extract RNA, with RNA quality determined with an
Agilent Bioanalyzer. An RNA integrity number of 7 used as the minimum
cut-off value.66 Based on the amount of RNA, samples from each mouse of
the same strain were evenly pooled.
The MouseRef-8 v2 BeadChip (Illumina, USA) was used to expression
profile 25,698 transcripts from the murine genome. A Bead Array Reader
was used to scan the BeadChip, with raw data exported using the Illumina
Genome Studio software (v2011.1). Using the lumi package in R (from the
Bioconductor software suite (www.bioconductor.org), results were log2-
transformed and normalized with Robust Spline Normalization. All data
have been made publically available at http://130.95.9.22/webqtl.html.
Quantitative real-time PCR
RNA samples from CC RI and founder strains were quantified using the
Nanodrop (Thermo) and normalized for concentration for cDNA synthesis.
cDNA synthesis was performed using Superscript IV VILO Reverse
Transcription Kit (Thermo), as per the manufacturer’s instructions. TaqMan
gene expression assays (Thermo) were used for quantification of mRNA
levels of Myo18b (Mm01201863_m1), Cep128 (Mm00725257_m1), and
Tnni3k (Mm00621993_m1) genes with Gapdh used as an endogenous
control (4352932E). Data were generated with the ViiA7 Real-Time PCR
System (Applied Biosystems). Samples were run in technical triplicates,
each group had two to five biological replicates. Relative quantification
analysis was performed using the ΔΔCT method.
Gene expression analysis, functional annotation, and trait
correlation
To assess expression data quality and sample grouping, PCA for all tested
strains was performed based on normalized cardiac expression data from
the MouseRef-8 v2 BeadChip (Illumina, USA) platform. PCA and pre-
processing of cardiac expression data were performed using the lumi
package in R available via the Bioconductor software suite (www.
bioconductor.org).
Heatmaps of the heart muscle gene expression dataset were generated
by performing hierarchical clustering using Multi Experiment Viewer
software (MEV v4.8.1 TIGR) with Euclidean Distance metric and default
parameters. The PANTHER (v12.0) classification system (http://pantherdb.
org/)29 was employed for statistical overrepresentation analysis using GO-
Slim Biological Process annotation dataset with default parameters. The
DAVID (v6.8) functional annotation tool (https://david.ncifcrf.gov/)30 was
used for functional annotation clustering against the GOTERM_BP_Direct
and KEGG_Pathway Databases. Resulting functional annotation clusters
were corrected for multiple testing by Bonferroni adjustment. Clusters with
corrected and p-values of p < 0.05 were considered significant.
The GeneNetwork67 (http://130.95.9.22/webqtl.html) was used for
correlation analyses between the cardiac expression dataset (with gene
expression threshold set to >7) and the quantitative traits. For the gene
expression dataset, robust spline normalized data were transformed to
produce Z-scores with a mean of 8 and a SD of 2 before entering into the
GeneNetwork mouse gene expression database. This one unit difference in
the transformed data was equivalent to a twofold difference in expression
level.
QTL mapping
Methods for mapping QTL using the CC strains have been described in
detail and with examples (see, e.g., refs 22,68,69). In summary, each CC strain
was genotyped using the 143,259 SNPs contained within the GigaMUGA
(GeneSeek, Lincoln, NB) mouse genotyping array. The genotype of each CC
strain was then compared with those of the eight CC founder strains, using
a subset of SNPs. Specifically, 120,521 of the GigaMUGA SNPs were
informative due to being reliably homozygous for each CC founder strain,
yet with at least one founder having the non-reference allele. By applying
the Hidden Markov Model algorithm in DOQTL, these informative SNPs
were used to determine the most likely founder CC strain that had
contributed the inferred haplotype at each chromosomal location for each
CC strain. To conduct genome-wide association mapping the inferred
haplotype probabilities were utilized by the GeneMiner online tool64 at
http://130.95.9.124/Geniad2/ to interface with the R package QTLRel. A
kinship matrix was used with a mixed model analysis to adjust for possible
confounding due to cryptic relatedness between the CC strains as a
random effect. Regression coefficients for the additive genetic effects of
each one of the eight founder haplotypes were calculated at all genomic
loci assessed. A likelihood ratio test was used for statistical analysis of the
degree of association between loci and the specific trait in question.
Plots of the LODs scores were generated for each trait, with 1000
permutations used to determine significance thresholds. Threshold values
were chosen at a genome-wide permutation P-value of ≤0.05 (significant),
P < 0.10 (approaching significance), and P < 0.63 (suggestive). Two-LOD
drop support intervals for each QTL were calculated and additional 10 kb
intervals added to the boundaries to compensate for non-uniformity of
SNP distribution. To compare the haplotype effect of the eight CC founder
strains on each trait, coefficient plots were generated. Genome sequences
from the Wellcome Trust Sanger Institute Mouse Genomes Project were
used to identify candidate genes within each QTL region. The GeneMiner
program was used to prioritize SNPs likely to alter protein structure and/or
function that were within the QTL and present in the founder strain/s
identified as conferring the trait being analyzed.
SNP validation
Effects of identified SNPs were assessed using Variant Effect Predictor (VEP)
software https://asia.ensembl.org/Tools/VEP (Ensembl release 93). VEP
utilizes the SIFT (Sorting Intolerant From Tolerant) program to predict
whether an amino acid substitution affects protein function.70 The SIFT
score is the normalized probability that the amino acid change is tolerated.
Substitutions with scores less than 0.05 are predicted to be deleterious.
The PCR was performed on mouse tail tip DNA, targeting selected
genomic regions using Phusion® High-Fidelity DNA Polymerase (New
England Biolabs). PCR fragments were purified using the NucleoSpin® Gel
and PCR Clean-up kit (MACHEREY-NAGEL). Sanger sequencing was
performed at the Micromon facility (Monash University). Sequencing
alignment and SNP analysis were performed using the DNASTAR MegAlign
tool (Lasergene® Core).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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